Zacks Investment Research on MSN
Gear up for Domino's Pizza (DPZ) Q4 earnings: Wall Street estimates for key metrics
Analysts on Wall Street project that Domino's Pizza (DPZ) will announce quarterly earnings of $5.36 per share in its forthcoming report, representing an increase of 9.6% year over year. Revenues are ...
The authorities took the injured bird to a rehabilitation center in New Jersey, which is working to stabilize it to allow for ...
Ryan Garcia is a supremely talented fighter at a career crossroads. Can he lock in and finally win a world championship?
First and only all-oral, fixed-duration regimen designed to provide CLL patients with the potential to experience time off treatment –– Approval expands Genentech’s fixed-duration portfolio by ...
LGBTQ Nation on MSN
HIV impacts hundreds of thousands of women. Here’s how.
HIV has long been thought of as a disease that primarily impacts gay men. That's wrongheaded.
MAJESTY, the first global Phase III study in primary membranous nephropathy, met its primary endpoint of complete remission at two years –– Up to 30% of people with membranous nephropathy progress to ...
Nodular sclerosis Hodgkin lymphoma is the most common subtype. It often starts in lymph nodes in the chest or neck and is ...
Novocure announced today that the U.S. Food and Drug Administration (FDA) approved Optune Pax® for the treatment of adult ...
Daniel Kirby, Chief Commercial Officer of Iovance, stated, “The real world Amtagvi data with impressive response rates, paired with unprecedented five-year durability and survival data, demonstrate a ...
Novocure (NASDAQ: NVCR) announced today that the U.S. Food and Drug Administration (FDA) approved Optune Pax (R) for the treatment of adult patients with locally advanced pancreatic cancer concomitant ...
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal ...
Lund, Sweden - February 10, 2026 -Active Biotech (NASDAQ Stockholm: ACTI) today received positive feedback on its clinical proof-of-concept trial with tasquinimod in myelofibrosis. The study will now ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results